5-HT3 Receptor Antagonist (Ramosetron) vs Loperamide for the Treatment of Low Anterior Resection Syndrome(RALARS)

Safety & Efficacy of 5-HT3 Receptor Antagonist (Ramosetron) Versus Loperamide for the Treatment of Low Anterior Resection Syndrome (RALLARS): Multicenter Randomized Controlled Trial

Safety & Efficacy of 5-HT3 Receptor Antagonist (Ramosetron) versus Loperamide for the Treatment of Low Anterior Resection Syndrome (RALLARS): Multicenter Randomized Controlled Trial

Inclusion Criteria:

• mid and low rectal cancer (AV<15cm)
• stage II, III, preop long-course CCRT, then ileostomy repair
• about 1~12 months after operation (no stomy)
• about 1~6 months after ileostomy repair
• major LARS

Exclusion Criteria:

• recurred rectal cancer
• stage IV
• IBD
• uncontrolled preoperative fecal incontinence or constipation